Today, WebMD Health Corp. (NASDAQ: WBMD) announced new features and functionality for its Healthy Target behavior change program that connects seamlessly with Apple’s HealthKit and provides users with powerful new ways to capture, visualize and understand health information from a broad range of biometric devices.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402511-web-md-updates-healthy-target-behavior-change-program-apple-healthkit/
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
Hologic, Inc. (NASDAQ: HOLX) is kicking off Breast Cancer Awareness Month with the announcement that the Company's groundbreaking 3D mammography exam, available on the Selenia Dimensions platform, will be introduced to consumers today as Genius 3D Mammography. Hologic’s Genius 3D Mammography is the only 3D exam approved by the FDA as clinically superior to traditional mammography.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7254155-hologic-new-consumer-awareness-campaign-mammography-technology/
EUROPEAN MICROWAVE WEEK - Peregrine Semiconductor Corp. (NASDAQ: PSMI), founder of RF SOI (silicon on insulator) and pioneer of advanced RF solutions, announces the expansion of its integrated product portfolio into DC and X-band frequencies. Today, Peregrine introduces two new integrated products–a True DC switch and an X-band core chip. Built on Peregrine's UltraCMOS® technology, both products integrate RF, digital and analog components onto a single chip. While integration has traditionally offered high-volume markets the benefit of lower cost, Peregrine uses intelligent integration to offer performance advantages in high-performance markets. Peregrine's integrated products offer benefits such as configurability, flexibility, reliability, repeatability, ease-of-use, a reduced form factor and enhanced performance.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7311051-peregrine-semiconductor-expands-integrated-product-portfolio/
Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
Last night, WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, honored its 2014 Health Hero winners at an awards ceremony hosted by Good Morning America co-anchor Robin Roberts. This year’s Health Heroes, who were recognized for meeting a health challenge and giving back to others, were Carson Daly, Michael J. Fox, Dr. Harold S. Koplewicz, Dr. Frank Papay, Zarin Ibnat Rahman and Martha Stewart.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7282553-webmd-inaugural-health-hero-awards-2014/
On Thursday, employees of global branded play leader, Hasbro, Inc. (NASDAQ:HAS), became holiday ‘elves’ as they celebrated the second Global Day of Joy, a volunteer initiative designed to spread cheer and bring positive change to thousands of children in 33 countries. From delivering toys and games to children and providing meals for the homeless to renovating playrooms and hosting special Hasbro Game Day events, Team Hasbro employees volunteered with more than 100 charitable organizations worldwide to make a difference through the power of volunteerism.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7389351-hasbro-second-global-day-of-joy-charitable-employees-volunteer-community-service-projects/
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the initiation of production of The PBA Film Project (working title), the first-ever documentary to provide an intimate look at real people living with a little-known neurologic condition called PseudoBulbar Affect (PBA). The award-winning filmmaker team of The PBA Film Project includes co-directors Doug Blush and Lisa Klein (Of Two Minds) and producer Julian Cautherley (The Crash Reel).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7266955-avanir-pharmaceuticals-pseudobulbar-affect-pba-documentary/
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Texas Instruments (TI) (NASDAQ: TXN) today announced the new SimpleLink™ ultra-low power wireless microcontroller (MCU) platform that helps customers go battery-less with energy harvesting or enjoy always-on, coin cell-powered operation for multiple years. With this industry-first technology, customers have the flexibility to develop products that support multiple wireless connectivity standards using a single-chip and identical RF design. The SimpleLink ultra-low power platform supports Bluetooth® low energy, ZigBee®, 6LoWPAN, Sub-1 GHz, ZigBee RF4CE™ and proprietary modes up to 5Mbps. This platform expands TI’s SimpleLink portfolio, the broadest, lowest power and easiest to use wireless connectivity offering in the industry for the Internet of Things (IoT). For more information, visit www.ti.com/simplelinkulp.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70647527-texas-instruments-simplelink/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
RealNetworks, Inc. (NASDAQ: RNWK) today announced the launch of RealTimes™, an innovative new app and service. RealTimes is the fastest and easiest way to get the most out of all of your personal photos and videos. It finds the best photos and videos you’ve taken and automatically turns them into RealTimes Stories™ that can be easily saved and shared.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7450951-realnetworks-video-photo-sharing-app/
